Bengaluru: In a significant healthcare collaboration, Novo Nordisk India has partnered with Emcure Pharma to commercialise Poviztra, a semaglutide injection (2.4 mg) indicated for chronic weight management.
This marks Emcure Pharma as the first Indian pharmaceutical company with exclusive rights to distribute and market Poviztra – the second brand of Wegovy – across India.
Novo Nordisk India Partnership with Emcure Pharma to Expand Access to Semaglutide
The partnership with Emcure Pharma underscores Novo Nordisk India’s commitment to making its innovative semaglutide molecule accessible to more people living with overweight and obesity.
Through this collaboration, Emcure will strengthen the reach of Novo Nordisk’s obesity care solutions, particularly in regions beyond the company’s current operational footprint.
Also Read: Emcure Secures Exclusive Distribution Rights for Sanofi India’s Oral Anti-diabetic Drugs
Poviztra (semaglutide injection 2.4 mg) is a GLP-1-based medication indicated as an adjunct to a reduced-calorie diet and increased physical activity.
The first brand, Wegovy, was launched in India in June 2025. Clinical studies demonstrated that one in three participants achieved over 20% weight loss using the treatment.
Exclusive Distribution Rights Strengthen Emcure Pharma’s Position
As part of the agreement, Emcure Pharma will exclusively manage the commercialisation and marketing of Poviztra® across India.
The company aims to leverage its strong understanding of India’s diverse geographical markets and established marketing network to reach patients in need of advanced obesity management therapy.
Commenting on the collaboration, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, said, “Obesity is a serious chronic disease affecting millions of people in India. By joining hands with Emcure Pharma, we aim to expand access to high-quality, safe, and effective obesity treatment combining Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s robust marketing and distribution capabilities.”
Satish Mehta, CEO and Managing Director of Emcure Pharma, added, “We are proud to be the first Indian company to bring the world’s most widely trusted GLP-1-based weight loss molecule to India. With our nationwide reach and strong marketing infrastructure, we are confident in delivering Poviztra® to patients who need it most.”
Also Read: Emcure Pharmaceuticals Q1 FY26: Revenue at INR 2101 Cr, PAT Rises 41 Per Cent
Broader Access to Obesity Management Solutions
This Novo Nordisk India partnership with Emcure Pharma represents a major step toward improving accessibility to obesity care solutions across India.
The launch of Poviztra aligns with Novo Nordisk India’s long-term vision of addressing the growing burden of obesity through innovative and evidence-based treatment options.
